Literature DB >> 7999453

Breast cancer and pregnancy.

J A Petrek1.   

Abstract

Breast cancer treatment during pregnancy involves a host of psychosocial, ethical, religious, and even legal considerations, as well as medical multidisciplinary decisions, since the effect of treatment on the fetus must be considered. For example, breast or chest wall radiotherapy should be avoided. The absorbed fetal dosage is at least 5 cGy early in pregnancy and increases to several hundred cGy late in pregnancy to the fetal part immediately below the diaphragm. In the second and third trimesters, chemotherapy is associated with intrauterine growth retardation and prematurity in about half of the babies; the risk of birth defects is a concern in the first several weeks. Typical anesthetic agents readily reach the fetus but are not known to be teratogenic. Although abortion will allow full and comprehensive treatment to the mother, it is not known whether the procedure itself is therapeutic. Early in pregnancy, abortion deserves strong consideration, since the effects of treatment on the fetus will not be a consideration. The poor prognosis of pregnancy-associated breast cancer in the past is probably attributable to a combination of initial delay of diagnosis and possibly to unfavorable biologic characteristics of the hormonal milieu of pregnancy. When pregnant patients are matched stage for stage with controls, survivals seem equivalent, although pregnant patients present with more advanced disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7999453

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN: 1052-6773


  6 in total

1.  Pregnancy-associated breast cancer.

Authors:  B O Anderson
Journal:  West J Med       Date:  1996-02

2.  Factors influencing the effect of age on prognosis in breast cancer: population based study.

Authors:  N Kroman; M B Jensen; J Wohlfahrt; H T Mouridsen; P K Andersen; M Melbye
Journal:  BMJ       Date:  2000-02-19

3.  Pregnancy influences breast cancer stage at diagnosis in women 30 years of age and younger.

Authors:  B O Anderson; J A Petrek; D R Byrd; R T Senie; P I Borgen
Journal:  Ann Surg Oncol       Date:  1996-03       Impact factor: 5.344

4.  The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation.

Authors:  Adriana Valentini; Jan Lubinski; Tomasz Byrski; Parviz Ghadirian; Pal Moller; Henry T Lynch; Peter Ainsworth; Susan L Neuhausen; Jeffrey Weitzel; Christian F Singer; Olufunmilayo I Olopade; Howard Saal; Dominique Stoppa Lyonnet; William D Foulkes; Charmaine Kim-Sing; Siranoush Manoukian; Dana Zakalik; Susan Armel; Leigha Senter; Charis Eng; Eva Grunfeld; Anna M Chiarelli; Aletta Poll; Ping Sun; Steven A Narod
Journal:  Breast Cancer Res Treat       Date:  2013-10-18       Impact factor: 4.872

5.  miR-21 Expression in Pregnancy-Associated Breast Cancer: A Possible Marker of Poor Prognosis.

Authors:  Beatriz A Walter; Gabriela Gómez-Macias; Vladimir A Valera; Mark Sobel; Maria J Merino
Journal:  J Cancer       Date:  2011-02-07       Impact factor: 4.207

6.  Breast cancer stroma frequently recruits fetal derived cells during pregnancy.

Authors:  Gil Dubernard; Sélim Aractingi; Michel Oster; Roman Rouzier; Marie-Christine Mathieu; Serge Uzan; Kiarash Khosrotehrani
Journal:  Breast Cancer Res       Date:  2008-02-13       Impact factor: 6.466

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.